The company is racing to reassure markets that it can navigate patent expirations for semaglutide - the active ingredient in its anti-obesity drugs Ozempic and Wegovy franchises, in the early 2030s
The company is racing to reassure markets that it can navigate patent expirations for semaglutide - the active ingredient in its anti-obesity drugs Ozempic and Wegovy franchises, in the early 2030s
<iframe src="https://hindustansphere.com/embed/cluster/c6ccbfda2cac7dacf8e3b61ab531ea08a3e4a800" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Novo Nordisk aims to launch more than five blockbuster drugs by 2030: CEO"></iframe>
